430 related articles for article (PubMed ID: 32567995)
1. Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation.
Kumar D; Kumari K; Vishvakarma VK; Jayaraj A; Kumar D; Ramappa VK; Patel R; Kumar V; Dass SK; Chandra R; Singh P
J Biomol Struct Dyn; 2021 Aug; 39(13):4671-4685. PubMed ID: 32567995
[TBL] [Abstract][Full Text] [Related]
2.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
3. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
Ancy I; Sivanandam M; Kumaradhas P
J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
[TBL] [Abstract][Full Text] [Related]
4. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target.
Kundu D; Selvaraj C; Singh SK; Dubey VK
J Biomol Struct Dyn; 2021 Jun; 39(9):3428-3434. PubMed ID: 32362243
[TBL] [Abstract][Full Text] [Related]
5. Molecular docking and simulation studies of natural compounds of
Mitra D; Verma D; Mahakur B; Kamboj A; Srivastava R; Gupta S; Pandey A; Arora B; Pant K; Panneerselvam P; Ghosh A; Barik DP; Mohapatra PKD
J Biomol Struct Dyn; 2022 Aug; 40(12):5665-5686. PubMed ID: 33459176
[TBL] [Abstract][Full Text] [Related]
6. Finding potent inhibitors for COVID-19 main protease (M
Motiwale M; Yadav NS; Kumar S; Kushwaha T; Choudhir G; Sharma S; Singour PK
J Biomol Struct Dyn; 2022 Mar; 40(4):1534-1545. PubMed ID: 33030102
[TBL] [Abstract][Full Text] [Related]
7. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
[TBL] [Abstract][Full Text] [Related]
8. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
[TBL] [Abstract][Full Text] [Related]
9. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
10. Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.
Yadav R; Imran M; Dhamija P; Chaurasia DK; Handu S
J Biomol Struct Dyn; 2021 Oct; 39(17):6617-6632. PubMed ID: 32715956
[TBL] [Abstract][Full Text] [Related]
11. Understanding the binding affinity of noscapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures.
Kumar D; Kumari K; Jayaraj A; Kumar V; Kumar RV; Dass SK; Chandra R; Singh P
J Biomol Struct Dyn; 2021 Apr; 39(7):2659-2672. PubMed ID: 32362235
[TBL] [Abstract][Full Text] [Related]
12. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
[TBL] [Abstract][Full Text] [Related]
13. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an
Majumder R; Mandal M
J Biomol Struct Dyn; 2022 Feb; 40(2):696-711. PubMed ID: 32897138
[TBL] [Abstract][Full Text] [Related]
14.
Kumar R; Kumar R; Tanwar P
J Biomol Struct Dyn; 2022 Oct; 40(16):7394-7407. PubMed ID: 33715592
[TBL] [Abstract][Full Text] [Related]
15. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study.
Das S; Sarmah S; Lyndem S; Singha Roy A
J Biomol Struct Dyn; 2021 Jun; 39(9):3347-3357. PubMed ID: 32362245
[TBL] [Abstract][Full Text] [Related]
16. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
[TBL] [Abstract][Full Text] [Related]
17. Computational studies on the design of NCI natural products as inhibitors to SARS-CoV-2 main protease.
Durgam L; Guruprasad L
J Biomol Struct Dyn; 2023 Jun; 41(9):3741-3751. PubMed ID: 35333147
[TBL] [Abstract][Full Text] [Related]
18. Potential of NO donor furoxan as SARS-CoV-2 main protease (M
Al-Sehemi AG; Pannipara M; Parulekar RS; Patil O; Choudhari PB; Bhatia MS; Zubaidha PK; Tamboli Y
J Biomol Struct Dyn; 2021 Sep; 39(15):5804-5818. PubMed ID: 32643550
[TBL] [Abstract][Full Text] [Related]
19. Cyanobacterial metabolites as promising drug leads against the M
Naidoo D; Roy A; Kar P; Mutanda T; Anandraj A
J Biomol Struct Dyn; 2021 Oct; 39(16):6218-6230. PubMed ID: 32691680
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an
Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
J Biomol Struct Dyn; 2021 Aug; 39(12):4362-4374. PubMed ID: 32568613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]